Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the safety of using the
[5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide]
([11C]CPPC) radiotracer in positron emission tomography (PET) imaging of people with
amyotrophic lateral sclerosis (ALS). The investigators are also interested to see whether use
of this radiotracer reveals imaging differences between patients with ALS and healthy
patients.